Use: Labeled indications
- 1.
Full indications and usage US FDA label
1. INDICATIONS AND USAGE BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) 1.1 Hypertension BYSTOLIC is indicated for the treatment of hypertension, to lower blood pressure [see Clinical Studies (14.1)].
BYSTOLIC may be used alone or in combination with other antihypertensive agents [see Drug Interactions (7)]. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs.
There are no controlled trials demonstrating risk reduction with BYSTOLIC. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).
These considerations may guide selection of therapy.
Contraindications
4. CONTRAINDICATIONS BYSTOLIC is contraindicated in the following conditions: Severe bradycardia Heart block greater than first degree Patients with cardiogenic shock Decompensated cardiac failure Sick sinus syndrome (unless a permanent pacemaker is in place) Patients with severe hepatic impairment (Child-Pugh >B) Patients who are hypersensitive to any component of this product.
Severe bradycardia (4) Heart block greater than first degree (4) Patients with cardiogenic shock (4) Decompensated cardiac failure (4) Sick sinus syndrome (unless a permanent pacemaker is in place) (4) Patients with severe hepatic impairment (Child-Pugh >B) (4) Hypersensitive to any component of this product (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2. DOSAGE AND ADMINISTRATION Can be taken with and without food. Individualize to the needs of the patient and monitor during up-titration. (2) Hypertension: Most patients start at 5 mg once daily. Dose can be increased at 2-week intervals up to 40 mg. (2.1) 2.1 Hypertension The dose of BYSTOLIC must be individualized to the needs of the patient.
For most patients, the recommended starting dose is 5 mg once daily, with or without food, as monotherapy or in combination with other agents. For patients requiring further reduction in blood pressure, the dose can be increased at 2-week intervals up to 40 mg. A more frequent dosing regimen is unlikely to be beneficial.
Renal Impairment In patients with severe renal impairment (ClCr less than 30 mL/min) the recommended initial dose is 2.5 mg once daily; titrate up slowly if needed. BYSTOLIC has not been studied in patients receiving dialysis [see Clinical Pharmacology (12.4)]. Hepatic Impairment In patients with moderate hepatic impairment, the recommended initial dose is 2.5 mg once daily; titrate up slowly if needed.
BYSTOLIC has not been studied in patients with severe hepatic impairment and therefore it is not recommended in that population [see Clinical Pharmacology (12.4)]. 2. 2 Subpopulations Geriatric Patients It is not necessary to adjust the dose in the elderly [see use in Specific Populations (8.5)]. CYP2D6 Polymorphism No dose adjustments are necessary for patients who are CYP2D6 poor metabolizers.
The clinical effect and safety profile observed in poor metabolizers were similar to those of extensive metabolizers [see Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
Renal Disease The apparent clearance of nebivolol was unchanged following a single 5 mg dose of BYSTOLIC in patients with mild renal impairment (ClCr 50 to 80 mL/min, n=7), and it was reduced negligibly in patients with moderate (ClCr 30 to 50 mL/min, n=9), but clearance was reduced by 53% in patients with severe renal impairment (ClCr <30 mL/min, n=5). No studies have been conducted in patients on dialysis [see Dosage and Administration (2.1)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Pediatric studies in ages newborn to 18 years old have not been conducted because of incomplete characterization of developmental toxicity and possible adverse effects on long-term fertility [see Nonclinical Toxicology (13.1)]. Juvenile Animal Toxicity Data Daily oral doses of nebivolol to juvenile rats from post-natal day 14 to post-natal day 27 showed sudden unexplained death at exposures equal to those in human poor metabolizers given a single dose of 10 mg.
No mortality was seen at half the adult human exposure. In surviving rats, cardiomyopathy was seen at exposures greater than or equal to the human exposure. Male rat pups exposed to twice the human exposure showed decreases in total sperm count as well as decreases in the total and percentage of motile sperm.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 2800 patients in the U.S. sponsored placebo-controlled clinical hypertension studies, 478 patients were 65 years of age or older. No overall differences in efficacy or in the incidence of adverse events were observed between older and younger patients.
Dosage forms
Philippines
- Tablet: 2.5 mg, 5 mg
Registered products in the Philippines
53 products registered with the Food and Drug Administration (FDA) Philippines list Nebivolol as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Nebivolol HCl volol HCl (1 product). Products registered under these spellings are included in the table and marked.
All registered products53
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Anvera 2.5Nebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12081-03 | Jun 9, 2027 | |
Anvera 5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12080-10 | Jun 9, 2032 | |
Arvian 2.5Nebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12081-05 | Jun 9, 2027 | |
Arvian 5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12080-11 | Jun 9, 2027 | |
BivololNebivolol (as hydrochloride) | 5mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories Ltd.India | MedEthix, Inc.Importer: I.E. Medica, Inc. | DR-XY46826 | Feb 11, 2027 | |
BivoproNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-12080-09 | Jun 9, 2032 | |
HeartivolNebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-12081-02 | Jun 9, 2032 | |
NabizNebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc. | DRP-14604-02 | Oct 26, 2028 | |
NabizNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc. | DRP-14603-02 | Oct 26, 2028 | |
Nebi-FlowNebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14604-01 | Oct 26, 2028 | |
NebicarNebivolol hydrochloride | 5 mg TabletAlu/PVC Blister Pack x 15s (Box of 60s) | RxVAT-exempt | Micro Labs LimitedIndia | Zuellig Pharma CorporationImporter: OEP Philippines, Inc. | DRP-12857 | Jul 5, 2031 | |
NebigoNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-12080-02 | Jun 9, 2032 | |
NebilNebivolol (as hydrochloride) | 2.5 mg TabletAlu/ Alu Blister Pack x 7’s (Box of 14’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY41164 | Aug 16, 2031 | |
NebilNebivolol (as hydrochloride) | 5mg TabletAlu-Alu Blister Pack of 7's (Box of 14’s) | RxVAT-exempt | Getz Pharma (Pvt.), Ltd.Pakistan | Importer: Getz Pharma (Phils.), Inc. | DR-XY41163 | Aug 16, 2031 | |
NebilaxNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma IncImporter: Ambica International Corporation | DRP-12080-03 | Jun 9, 2027 | |
NebiletNebivolol (as Hydrochloride) | 5 mg TabletClear PVC/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Berlin Chemie AGGermany | Importer: A. Menarini Philippines, Inc. | DRP-12874 | Jul 10, 2029 | |
NebilolNebivolol (as hydrochloride) | 5 mg TabletAlu-Alu Blister Pacls x 10's (B ox of 30's) | RxVAT-exempt | Hetero Labs Limited (Unit III)India | Camber Pharmaceuticals, Inc. | DRP-17034 | Sep 12, 2030 | |
Nebiphil-2.5Nebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14604 | Oct 26, 2028 | |
Nebiphil-5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14603 | Oct 26, 2028 | |
Nebivio 2.5Nebivolol HCl | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's & 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16617-01 | May 20, 2030 | |
Nebivio 5Nebivolol HCl | 5 mg TabletAlu / Alu Blister Pack x 10's (Box of 10's & 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16616-01 | May 20, 2030 | |
NebivolNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-12080-06 | Jun 9, 2032 | |
Nebivomed-2.5Nebivolol HCl | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's & 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-16617 | May 20, 2030 | |
Nebivomed-5Nebivolol HCl | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's & 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-16616 | May 20, 2030 | |
Nebizyd 2.5Nebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12081-04 | Jun 9, 2027 | |
Nebizyd 5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation | DRP-12080-12 | Jun 9, 2027 | |
NebothrobNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-12080-07 | Jun 9, 2027 | |
Nebstyle 5Nebivolol (as hydrochloride) | 5mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (Unit III)India | AAA Pharma, Inc. | DR-XY48809 | Jul 12, 2028 | |
NEBYNebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Innogen Pharmaceuticals, Inc.Importer: AMB HK Enterprises Inc. | DRP-14604-03 | Oct 26, 2028 | |
NebyNebivolol HCl | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's & 30's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-16617-02 | May 20, 2030 | |
NebyNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Innogen Pharmaceuticals, Inc.Importer: AMB HK Enterprises Inc. | DRP-14603-03 | Oct 26, 2028 | |
5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10's & 30's) | Rx | Corona Remedies Pvt. Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-16616-02 | May 20, 2030 | ||
NeviblocNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | AJANTA PHARMA LIMITEDIndia | THE CATHAY YSS DISTRIBUTORS CO., INC. | DR-XY39070 | Feb 21, 2029 | |
NevodioNebivolol (as Hydrochloride) | 5 mg TabletPolycellonium strip x 10's (Box of 30's) | RxVAT-exempt | PT Dexa MedicaIndonesia | Glorious Dexa Mandaya, Inc. | DR-XY48362 | Sep 19, 2027 | |
Nevolf-2.5Nebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-12081 | Jun 9, 2032 | |
Nevolf-5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-12080 | Jun 9, 2032 | |
NitroxelNebivolol (as hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Unilab, Inc.Importer: Ambica International Corporation | DRP-12081-01 | Jun 9, 2027 | |
NitroxelNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Unilab, Inc.Importer: Ambica International Corporation | DRP-12080-04 | Jun 9, 2027 | |
NoneNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-12080-01 | Jun 9, 2027 | |
NoneNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-12080-13 | Jun 9, 2027 | |
NoneNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-12080-15 | Jun 9, 2027 | |
NoneNebivolol (as Hydrochloride) | 5 mg TabletClear PVC/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Berlin Chemie AGGermany | Philusa CorporationImporter: A. Menarini Philippines, Inc.Trader: A. Menarini Asia Pacific Holdings, Pte. Ltd. | DRP-12874-01 | Jul 10, 2029 | |
NoneNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Ritemed Phils., Inc.Importer: AMB HK Enterprises | DRP-14603-04 | Oct 26, 2028 | |
Saphnebiv-G2.5Nebivolol (As Hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack X 10's (Box of 30's and 100's) | RxVAT-exempt | Global Pharma Healthcare Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-18751 | Sep 3, 2031 | |
Saphnebiv-G5Nebivolol (as Hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Global Pharma Healthcare Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-18750 | Sep 3, 2031 | |
SynbetaNebivolol (as hydrochloride) | 5 mg TabletAlu/Clear PVC/PVDC Blister Pack x 14's (Box of 28's and 280's) | RxVAT-exempt | Synmosa Biopharma Corporation (Synmosa Plant)Taiwan | Synmosa Biopharma Philippines Inc. | DRP-17447 | Jun 18, 2032 | |
Toricard-5Nebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY37962 | May 20, 2030 | |
UnbrandedNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation | DRP-12080-05 | Jun 9, 2032 | |
UnbrandedNebivolol (as hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-12080-08 | Jun 9, 2032 | |
UnbrandedNebivolol (as hydrochloride) | 5mg TabletAlu/Alu Blister Pack x 10's (Box of 30’s & 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rose Pharmacy, IncorporatedImporter: Ambica International Corporation | DRP-12080-14 | Jun 9, 2027 | |
Vilolo 2.5Nebivolol (as Hydrochloride) | 2.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | 4Care Lifescience Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13442 | Feb 20, 2028 | |
Vilolo-5Nebivolol (as Hydrochloride) | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | 4Care Lifescience Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13443 | Feb 20, 2028 | |
(no brand name)Nebivolol (as hydrochloride) | 5mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories Ltd.India | I.E. Medica, Inc. | DR-XY46827 | Feb 11, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3. DOSAGE FORMS AND STRENGTHS BYSTOLIC is available as tablets for oral administration containing nebivolol hydrochloride equivalent to 2.5, 5, 10, and 20 mg of nebivolol. BYSTOLIC tablets are triangular-shaped, biconvex, unscored, differentiated by color and are engraved with “ FL ” on one side and the number of mg (2 ½, 5, 10, or 20) on the other side. Tablets: 2.5, 5, 10, 20 mg (3)
Warnings/Precautions
Warnings and precautions (US label) US FDA label
5. WARNINGS AND PRECAUTIONS Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. (5.1) Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor (5.5) 5.1 Abrupt Cessation of Therapy Do not abruptly discontinue BYSTOLIC therapy in patients with coronary artery disease.
Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients with coronary artery disease following the abrupt discontinuation of therapy with β-blockers. Myocardial infarction and ventricular arrhythmias may occur with or without preceding exacerbation of the angina pectoris.
Caution patients without overt coronary artery disease against interruption or abrupt discontinuation of therapy. As with other β-blockers, when discontinuation of BYSTOLIC is planned, carefully observe and advise patients to minimize physical activity. Taper BYSTOLIC over 1 to 2 weeks when possible. If the angina worsens or acute coronary insufficiency develops, re-start BYSTOLIC promptly, at least temporarily. 5. 2 Angina and Acute Myocardial Infarction BYSTOLIC was not studied in patients with angina pectoris or who had a recent MI. 5. 3 Bronchospastic Diseases In general, patients with bronchospastic diseases should not receive β-blockers. 5. 4 Anesthesia and Major Surgery Because beta-blocker withdrawal has been associated with an increased risk of MI and chest pain, patients already on beta-blockers should generally continue treatment throughout the perioperative period.
If BYSTOLIC is to be continued perioperatively, monitor patients closely when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used. If β-blocking therapy is withdrawn prior to major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.
The β-blocking effects of BYSTOLIC can be reversed by β-agonists, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Additionally, difficulty in restarting and maintaining the heartbeat has been reported with β-blockers. 5. 5 Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at anytime during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting).
If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment. 5. 6 Thyrotoxicosis β-blockers may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm. 5. 7 Peripheral Vascular Disease β-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. 5. 8 Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. 5. 9 Use with CYP2D6 Inhibitors Nebivolol exposure increases with inhibition of CYP2D6 [see Drug Interactions (7)].
The dose of BYSTOLIC may need to be reduced. 5.1 0 Impaired Renal Function Renal clearance of nebivolol is decreased in patients with severe renal impairment. BYSTOLIC has not been studied in patients receiving dialysis [see Clinical Pharmacology (12.4) and Dosage and Administration (2.1)]. 5.1 1 Impaired Hepatic Function Metabolism of nebivolol is decreased in patients with moderate hepatic impairment.
BYSTOLIC has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.4) and Dosage and Administration (2.1)]. 5.1 2 Risk of Anaphylactic Reactions While taking β-blockers, patients with a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. 5.1 3 Pheochromocytoma In patients with known or suspected pheochromocytoma, initiate an α-blocker prior to the use of any β-blocker.
Drug interactions
- 7. DRUG INTERACTIONS CYP2D6 enzyme inhibitors may increase nebivolol levels. (7.1)
- Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2)
- Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3)
- Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4)
7.1 CYP2D6 Inhibitors
7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)].
7.2 Hypotensive Agents
7.2 Hypotensive Agents Do not use BYSTOLIC with other β-blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, because the added β-blocking action of BYSTOLIC may produce excessive reduction of sympathetic activity. In patients who are receiving BYSTOLIC and clonidine, discontinue BYSTOLIC for several days before the gradual tapering of clonidine.
7.3 Digitalis Glycosides
7.3 Digitalis Glycosides Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.
7.4 Calcium Channel Blockers
7.4 Calcium Channel Blockers BYSTOLIC can exacerbate the effects of myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
12.3 Pharmacokinetics Nebivolol is metabolized by a number of routes, including glucuronidation and hydroxylation by CYP2D6.
The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor metabolizers and exposure to d-nebivolol is substantially increased in poor metabolizers.
DRUG INTERACTIONS CYP2D6 enzyme inhibitors may increase nebivolol levels.
( 7.4 ) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology ( 12.5 )] . 7.2 Hypotensive Agents Do not use BYSTOLIC with other β-blockers.
Adverse reactions
6. ADVERSE REACTIONS Most common adverse reactions (6.1): Headache, fatigue To report SUSPECTED ADVERSE REACTIONS, Contact AbbVie Inc. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Studies Experience
6.1 Clinical Studies Experience BYSTOLIC has been evaluated for safety in patients with hypertension and in patients with heart failure. The observed adverse reaction profile was consistent with the pharmacology of the drug and the health status of the patients in the clinical trials. Adverse reactions reported for each of these patient populations are provided below.
Excluded are adverse reactions considered too general to be informative and those not reasonably associated with the use of the drug because they were associated with the condition being treated or are very common in the treated population. The data described below reflect worldwide clinical trial exposure to BYSTOLIC in 6545 patients, including 5038 patients treated for hypertension and the remaining 1507 subjects treated for other cardiovascular diseases.
Doses ranged from 0.5 mg to 40 mg. Patients received BYSTOLIC for up to 24 months, with over 1900 patients treated for at least 6 months, and approximately 1300 patients for more than one year. HYPERTENSION: In placebo-controlled clinical trials comparing BYSTOLIC with placebo, discontinuation of therapy due to adverse reactions was reported in 2.8% of patients treated with nebivolol and 2.2% of patients given placebo.
The most common adverse reactions that led to discontinuation of BYSTOLIC were headache (0.4%), nausea (0.2%) and bradycardia (0.2%). Table 1 lists treatment-emergent adverse reactions that were reported in three 12-week, placebo-controlled monotherapy trials involving 1597 hypertensive patients treated with either 5 mg, 10 mg, or 20-40 mg of BYSTOLIC and 205 patients given placebo and for which the rate of occurrence was at least 1% of patients treated with nebivolol and greater than the rate for those treated with placebo in at least one dose group.
Table 1. Treatment-Emergent Adverse Reactions with an Incidence (over 6 weeks) ≥ 1% in BYSTOLIC-Treated Patients and at a Higher Frequency than Placebo-Treated Patients System Organ Class – Preferred Term Placebo (n = 205) (%) Nebivolol 5 mg (n = 459) (%) Nebivolol 10 mg (n = 461) (%) Nebivolol 20-40 mg (n = 677) (%) Cardiac Disorders Bradycardia 0 0 0 1 Gastrointestinal Disorders Diarrhea 2 2 2 3 Nausea 0 1 3 2 General Disorders Fatigue 1 2 2 5 Chest pain 0 0 1 1 Peripheral edema 0 1 1 1 Nervous System Disorders Headache 6 9 6 7 Dizziness 2 2 3 4 Psychiatric Disorders Insomnia 0 1 1 1 Respiratory Disorders Dyspnea 0 0 1 1 Skin and subcutaneous Tissue Disorders Rash 0 0 1 1 Listed below are other reported adverse reactions with an incidence of at least 1% in the more than 4300 patients treated with BYSTOLIC in controlled or open-label trials except for those already appearing in Table 1, terms too general to be informative, minor symptoms, or adverse reactions unlikely to be attributable to drug because they are common in the population.
These adverse reactions were in most cases observed at a similar frequency in placebo-treated patients in the controlled studies. Body as a W hole: asthenia. Gastrointestinal System Disorders: abdominal pain Metabolic and Nutritional Disorders: hypercholesterolemia Nervous System Disorders: paraesthesia
6.2 Laboratory Abnormalities
6.2 Laboratory Abnormalities In controlled monotherapy trials of hypertensive patients, BYSTOLIC was associated with an increase in BUN, uric acid, triglycerides and a decrease in HDL cholesterol and platelet count.
6.3 Postmarketing Experience
6.3 Postmarketing Experience The following adverse reactions have been identified from spontaneous reports of BYSTOLIC received worldwide and have not been listed elsewhere. These adverse reactions have been chosen for inclusion due to a combination of seriousness, frequency of reporting or potential causal connection to BYSTOLIC.
Adverse reactions common in the population have generally been omitted. Because these adverse reactions were reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency or establish a causal relationship to BYSTOLIC exposure: abnormal hepatic function (including increased AST, ALT and bilirubin), acute pulmonary edema, acute renal failure, atrioventricular block (both second and third degree), bronchospasm, erectile dysfunction, hypersensitivity (including urticaria, allergic vasculitis and rare reports of angioedema), hypotension, myocardial infarction, pruritus, psoriasis, Raynaud’s phenomenon, peripheral ischemia/claudication, somnolence, syncope, thrombocytopenia, various rashes and skin disorders, vertigo, and vomiting.
Adverse reaction frequency tables (US label) US FDA label
| System Organ Class – Preferred Term | Placebo (n = 205) (%) | Nebivolol 5 mg (n = 459) (%) | Nebivolol 10 mg (n = 461) (%) | Nebivolol 20-40 mg (n = 677) (%) |
| Cardiac Disorders | ||||
| Bradycardia | 0 | 0 | 0 | 1 |
| Gastrointestinal Disorders | ||||
| Diarrhea | 2 | 2 | 2 | 3 |
| Nausea | 0 | 1 | 3 | 2 |
| General Disorders | ||||
| Fatigue | 1 | 2 | 2 | 5 |
| Chest pain | 0 | 0 | 1 | 1 |
| Peripheral edema | 0 | 1 | 1 | 1 |
| Nervous System Disorders | ||||
| Headache | 6 | 9 | 6 | 7 |
| Dizziness | 2 | 2 | 3 | 4 |
| Psychiatric Disorders | ||||
| Insomnia | 0 | 1 | 1 | 1 |
| Respiratory Disorders | ||||
| Dyspnea | 0 | 0 | 1 | 1 |
| Skin and subcutaneous Tissue Disorders | ||||
| Rash | 0 | 0 | 1 | 1 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data regarding use of BYSTOLIC in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes. There are risks to the mother and fetus associated with poorly controlled hypertension in pregnancy. The use of beta blockers during the third trimester of pregnancy may increase the risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in the neonate [see Clinical Considerations].
Oral administration of nebivolol to pregnant rats during organogenesis resulted in embryofetal and perinatal lethality at doses approximately equivalent to the maximum recommended human dose (MRHD). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Neonates of women with hypertension, who are treated with beta-blockers during the third trimester of pregnancy, may be at increased risk for hypotension, bradycardia, hypoglycemia, and respiratory depression.
Observe newborns for symptoms of hypotension, bradycardia, hypoglycemia and respiratory depression and manage accordingly. Data Animal Data Nebivolol was shown to increase embryo-fetal and perinatal lethality in rats at approximately 1.2 times the MRHD or 40 mg/day on a mg/m 2 basis. Decreased pup body weights occurred at 1.25 and 2.5 mg/kg in rats, when exposed during the perinatal period (late gestation, parturition and lactation).
At 5 mg/kg and higher doses (1.2 times the MRHD), prolonged gestation, dystocia and reduced maternal care were produced with corresponding increases in late fetal deaths and stillbirths and decreased birth weight, live litter size and pup survival. These events occurred only when nebivolol was given during the perinatal period (late gestation, parturition and lactation).
Insufficient numbers of pups survived at 5 mg/kg to evaluate the offspring for reproductive performance. In studies in which pregnant rats were given nebivolol during organogenesis, reduced fetal body weights were observed at maternally toxic doses of 20 and 40 mg/kg/day (5 and 10 times the MRHD), and small reversible delays in sternal and thoracic ossification associated with the reduced fetal body weights and a small increase in resorption occurred at 40 mg/kg/day (10 times the MRHD).
No adverse effects on embryo-fetal viability, sex, weight or morphology were observed in studies in which nebivolol was given to pregnant rabbits at doses as high as 20 mg/kg/day (10 times the MRHD).
Mechanism of action
12.1 Mechanism of Action The mechanism of action of the antihypertensive response of BYSTOLIC has not been definitively established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral vascular resistance.
US FDA labelPharmacokinetics
The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor metabolizers and exposure to d-nebivolol is substantially increased in poor metabolizers.
Essentially all nebivolol was excreted as multiple oxidative metabolites or their corresponding glucuronide conjugates.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Nebivolol is metabolized by a number of routes, including glucuronidation and hydroxylation by CYP2D6. The active isomer (d-nebivolol) has an effective half-life of about 12 hours in CYP2D6 extensive metabolizers (most people), and 19 hours in poor metabolizers and exposure to d-nebivolol is substantially increased in poor metabolizers.
This has less importance than usual, however, because the metabolites, including the hydroxyl metabolite and glucuronides (the predominant circulating metabolites), contribute to β-blocking activity. Plasma levels of d–nebivolol increase in proportion to dose in EMs and PMs for doses up to 20mg. Exposure to l-nebivolol is higher than to d-nebivolol but l-nebivolol contributes little to the drug’s activity as d-nebivolol’s beta receptor affinity is > 1000-fold higher than l-nebivolol.
For the same dose, PMs attain a 5-fold higher Cmax and 10-fold higher AUC of d-nebivolol than do EMs. d-Nebivolol accumulates about 1.5-fold with repeated once-daily dosing in EMs. Absorption Absorption of BYSTOLIC is similar to an oral solution. The absolute bioavailability has not been determined. Mean peak plasma nebivolol concentrations occur approximately 1.5 to 4 hours post-dosing in EMs and PMs.
Food does not alter the pharmacokinetics of nebivolol. Under fed conditions, nebivolol glucuronides are slightly reduced. BYSTOLIC may be administered without regard to meals. Distribution The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations.
Metabolism Nebivolol is predominantly metabolized via direct glucuronidation of parent and to a lesser extent via N-dealkylation and oxidation via cytochrome P450 2D6. Its stereospecific metabolites contribute to the pharmacologic activity [see Drug Interactions (7)]. Elimination After a single oral administration of 14C-nebivolol, 38% of the dose was recovered in urine and 44% in feces for EMs and 67% in urine and 13% in feces for PMs.
Essentially all nebivolol was excreted as multiple oxidative metabolites or their corresponding glucuronide conjugates.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Bystolic · Allergan, Inc. [US FDA-approved label, version 31, August 1, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b8ad213-1dc8-454e-a524-075685c0e1a8
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .